Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

Afr Health Sci. 2022 Sep;22(3):506-511. doi: 10.4314/ahs.v22i3.54.

Abstract

Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.

Keywords: COVID-19; Invasive pulmonary aspergillosis; Uganda; critical illness.

MeSH terms

  • Adult
  • Antibodies, Viral
  • COVID-19 Drug Treatment
  • COVID-19*
  • Humans
  • Immunoglobulin G
  • Immunoglobulin M
  • Sensitivity and Specificity
  • Uganda

Substances

  • Immunoglobulin G
  • Immunoglobulin M
  • Antibodies, Viral